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TERMS AND ABBREVIATIONS 
Terms 
Cohort   A designated group of persons  
Cohort study An observational study in which a defined group of persons are 
classified on the basis of the presence or absence of a particular 
exposure (symptom) and then followed for a specified period to 
determine the development of disease in each group 
Incidence The number of new cases of a disease in a defined population, within a 
specified period 
Incidence rate The rate at which new events occur in a defined period, presented as 
the occurrence of new disease per 100 000 of person–time in the study 
Mortality rate An estimate of the proportion of a population that will die during a 
specified period, presented as the occurrence of death per 100 000 
person–time in the study 
Prevalence The number of cases of a given disease or symptom in a given 
population at a designated time  
 
Abbreviations  
CI   Confidence interval 
COPD   Chronic Obstructive Pulmonary Disease 
FEV1   Forced expiratory volume in 1 second 
HR   Hazard ratio 
ICD   International Statistical Classification of Diseases, Injuries and Death  
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IHD   Ischaemic Heart Disease 
IR   Incidence Rate 
MR    Mortality Rate 
OLD   Obstructive Lung Disease 
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INTRODUCTION 
Respiratory symptoms are one of the main reasons for contacting health-care professionals 
[1,2], particularly when the symptoms affect the quality of daily life [3]. Respiratory 
symptoms are common in all populations, and their prevalence and determinants have been 
studied extensively over the past 50 years [4-19]. Many more persons have respiratory 
symptoms than fulfil the clinical diagnosis of, for example, obstructive lung disease (OLD) 
[20,21]. Studies by Gulsvik and Lundbäck [9,20] showed a relation between respiratory 
symptoms and impairment of lung function. Respiratory symptoms are often markers of 
pathological conditions, primarily in the lungs and airways but also in the heart, chest wall 
and organs outside the chest. The symptoms are useful for helping physicians to establish 
diagnoses, interventions and treatment [22]. 
 
Respiratory tract symptoms  
Cough  
Cough is defined as a deep inspiration followed by a strong expiration against a closed glottis, 
which then opens with an expulsive flow of air, followed by a restorative inspiration. Cough 
is one of the defensive reflexes of the respiratory tract, as it ensures the removal of mucus, 
noxious substances and infectious organisms from the larynx, trachea and large bronchi 
[23,24]. Coughing can be initiated by a wide variety of inflammatory and mechanical changes 
in the airways and by inhalation of various chemical and mechanical irritants. Rapid, large 
changes in lung volume can cause cough, as can psychological reactions, such as laughter. 
The most sensitive sites for initiation of cough are the larynx and the tracheobronchial tree, 
especially the carina and the sites of bronchial branching, where cough receptors are 
frequently situated [25].  
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Cough is a symptom that affects many people. The prevalence varies between 8% and 30% 
[7,9,16,21,26,27] and is increasing with time [16,28]. Cough can be non-productive or 
productive, acute or chronic [26] and is one of the commonest respiratory tract symptoms for 
which persons seek
 
medical advice [29,30]. Quality of life is often impaired by acute and 
chronic cough [31-33], and health status improves significantly after specific therapy for a 
cough [34,35].  
 
Asthma-like symptoms 
The term „asthma‟ derives from the Greek verbal root „to blow‟ [36]. The medical definition 
has changed over time; it is currently defined as a chronic inflammatory disorder of the 
airways resulting in increased airway hyperresponsiveness, leading to episodes of wheezing, 
breathlessness, chest tightness and coughing. All symptoms are associated with reversible and 
variable airflow obstruction [37,38]. Wheezing is due to the turbulence of air passing through 
unusual narrowing (obstruction) of the air passages [39]. Because asthma is defined as 
reversible airway obstruction, the sense of breathlessness may be short and episodic, as 
attacks of breathlessness. Another sign of inflammation or airway hyperresponsiveness can be 
long-term cough [40], such as coughing for several weeks after a cold.  
As the pathogenesis of asthma is unclear, it follows that the definition of the symptoms is 
descriptive and inclusive. So far, there is no method for directly measuring the underlying 
inflammation in persons with asthma. Thus, in clinical practice, asthma is diagnosed on the 
basis of asthma-like symptoms alone or with the results of clinical tests for indirect 
measurement of airway inflammation. In epidemiological studies, asthma is usually described 
as „physician-diagnosed asthma‟, „self-reported asthma‟ or „asthma-like symptoms‟, such as 
wheezing, attacks of breathlessness or other symptoms that indicate airway 
hyperresponsiveness [9,41-45]. 
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The prevalence of asthma depends on how asthma is defined and varies between countries 
and among different areas in the same country [46]. In the Nordic countries, the prevalence 
varies from 3% to 15% [12,14,18,40,46]; the prevalence of self-reported asthma and asthma-
like symptoms has increased over the past 20 years [12,14,18].  
 
Dyspnoea 
The word „dyspnoea‟ comes from the Greek and means „painful or difficult to breath‟ [47]. 
Dyspnoea is the physician‟s term for the symptom of breathlessness or shortness of breath and 
is used to characterize a patient‟s experience of breathing discomfort. The experience derives 
from interactions among multiple physiological, psychological, social and environmental 
factors, and it may induce secondary physiological and behavioural responses. Dyspnoea can 
best be perceived and described by the individual who is experiencing it [48].  
The brain stem is central to our understanding of dyspnoea [47], as the cerebral respiratory 
centre receives input from a variety of chemical and mechanical receptors or emotions and 
from the lungs and chest wall, which determine the efferent breathing command [49]. A wide 
variety of conditions can give rise to dyspnoea, but by far the most common are disorders of 
the lungs and heart [23,50]. Other conditions related to dyspnoea include respiratory muscle 
weakness, late-stage pregnancy, anaemia, thyroid disorders, poor physical shape, panic 
disorder and anxiety. Dyspnoea can occur in healthy persons under stressful conditions, such 
as exercise and high altitude, and in patients with an underlying cardiopulmonary disorder, 
after little or no effort [49]. 
The prevalence of dyspnoea in the Nordic population varies between 3% and 25%, depending 
on age and level of exercise [7,16,18,28,40].  
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Respiratory symptom score 
The commonest method for recording health status in epidemiological studies is the 
questionnaire, with use of dichotomous variables (yes/no answers) for further analyses of 
associations between symptoms and relevant variables and outcome. If diseases occur as a 
continuum in the population, the symptoms related to the diseases should also occur as a 
continuum. Use of a scoring system is an alternative to use of dichotomous variables and has 
been used in studies of psychiatric disorders [51], quality of life [52] and respiratory diseases 
[53]. An asthma score consisting of a simple sum of the positive answers to eight questions on 
respiratory symptoms predicted outcomes related to asthma and improved the statistical 
power of the analyses [54].  
 
Airway irritants   
Smoking  
The number of daily smokers in Norway has decreased during the past few decades (Figure 
1). The percentages of men and women who smoked daily were 52% and 32%, respectively, 
in 1973 and 28% and 27%, respectively, in 2003. The decrease occurred in all age groups. In 
2003, daily smokers accounted for 26% of men and 24% of women aged 16–24 years and 
22% of men and 16% of women aged 65–74 years [55]. 
Smokers have more respiratory symptoms than non-smokers [5,6,15], and smoking cessation 
has a beneficial effect on remission of respiratory symptoms [56]. The association between 
smoking habits and morbidity is well known [57,58]. Smokers have higher risks for OLD 
[59,60], invasive pneumonia [61], ischaemic heart disease (IHD) [60,62,63] and lung cancer 
[60,63-65]. Even smokers who smoke 1–4 cigarettes per day have a higher risk for dying from 
IHD than non-smokers [66].  
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Figure 1. Numbers of daily smokers among men and women aged 16–74 years in 
Norway, 1973–2003. From reference [55] 
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Occupational exposure 
Having a job with heavy exposure to airborne particles increases the adjusted risk for OLD 
and lung cancer compared to those who are less exposed or unexposed [67,68]. The 
association between exposure to fluorides and respiratory symptoms such as dyspnoea and 
wheezing is well documented [69]. Blue-collar workers had a higher prevalence of respiratory 
symptoms than white-collar workers in a study of 1404 middle-aged Danish men [28]. 
Occupational exposure to airborne dust or fumes increased the occurrence of respiratory 
symptoms and asthma, independently of age, educational level and smoking habits in a cohort 
study of 2819 Norwegian men and women, with 11 years of follow-up [70].  
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Air pollution  
Indoor air pollution, with, for instance, mould or environment tobacco smoke, can cause 
respiratory symptoms and dysfunction in both adults and children [71-73]. With regard to 
outdoor air pollution, diesel exhaust particles appear to affect the airways more than road 
surface particles [74]. A study of men in Oslo followed for 27 years showed that air pollution 
can increase the risks for cause-specific mortality [75] and lung cancer [76].  
  
Population-based studies conducted before 2003 of mortality from all causes and from 
cardiovascular and pulmonary diseases and incidence of lung cancer related to 
respiratory symptoms 
Previous studies are summarized in Table 1. 
 
Mortality from all causes 
The mortality rates (MR) of men and women who reported persistent cough and phlegm were 
40% and 60% higher than those of asymptomatic persons in Norway [77]. Population-based 
studies elsewhere have confirmed that mortality is increased in association with symptoms of 
chronic mucus hypersecretion [78-85] as well as effort-related breathlessness [80]. Little data 
are available on the association between all-cause mortality and symptom scores [85], asthma-
like symptoms such as wheezing [81,83,85], attacks of breathlessness [83] and long-lasting 
cough after a cold. Two of the previous studies involved only men [78,80], and three involved 
fewer than 3000 persons [78,81,86]. Only three studies addressed populations with age spans 
of 20–70 years [79,83,85]. The longest follow-up was 27 years, but that study included only 
1500 persons [81]. No study was found that addressed the relation between respiratory 
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symptoms and mortality adjusted for occupational exposure to air pollution in addition to age 
and smoking habits. 
 
 
Mortality from respiratory disease 
Few population-based studies have focused on the association between respiratory symptoms 
and mortality from OLD [79,87] or pneumonia [88], although these diseases are the main 
causes of death from non-malignant respiratory disease [89]. Two population-based studies 
showed associations between cough and dyspnoea and mortality from a group of all 
respiratory diseases [80,85], and one showed an association between wheezing and mortality 
from respiratory disease [85]. Lange et al. [79] showed that persons who reported symptoms 
of chronic mucus hypersecretion had a higher risk for dying from OLD, and Vandentorren et 
al. [87] showed that persons reporting asthma or asthma symptoms had a higher risk for death 
from chronic obstructive lung disease (COPD).  
Large cohorts are needed to obtain a sufficient number of deaths to attain power in analysing 
the association between respiratory symptoms and cause-specific respiratory diseases for men 
and women separately. 
 
Mortality from cardiovascular disease 
Impaired lung function increases the risk for death from cardiovascular disease by twofold, 
independently of smoking [90], and the risk for cardiac arrhythmia is inversely associated 
with lung function [91]. Smaller population-based studies have indicated an association 
between respiratory symptoms and mortality from IHD [80,82,85,92]. Todd et al. [82] found 
an association between chronic cough and mortality from IHD in both sexes. Knuiman et al. 
[85], however found that this association was significant only for men. Two studies showed 
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increased risks for mortality from IHD among persons reporting moderate dyspnoea [80,85]. 
Two studies showed that persons with asthma or symptoms of asthma had a 20–40% higher 
risk for death from cardiovascular disease than those without asthma symptoms [87,92].  
The results diverge with regard to mortality from stroke. Todd et al. and Knuiman et al. 
[82,85] showed non-significant negative associations between chronic cough and mortality 
from stroke in both sexes, while Rosengren et al. [80] observed an increased risk for mortality 
from stroke among men who reported dyspnoea. No information was available on the 
association between respiratory symptoms and cause-specific mortality from cardiovascular 
disease by sex, adjusted for smoking habits and occupational exposure.  
 
Incidence of and mortality from lung cancer 
Although cigarette smoking might explain 80–85% of lung cancers in the Nordic countries 
[94], several studies have indicated an association between lung cancer and non-malignant 
pulmonary diseases, even among non-smokers or after adjustment for smoking habits [95-98]. 
Patients with COPD have an increased risk for lung cancer, even after adjustment for smoking 
habits. Moreover, this risk increases inversely with level of pulmonary function expressed as 
forced expiratory volume in one second (FEV1) [99].   
Respiratory symptoms are often markers of inflammatory processes in the lungs and airways, 
and might be present before other clinical manifestations. The literature concerning the 
association between respiratory symptoms and incidence of lung cancer was, however, sparse 
[8]. 
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AIMS  
The objectives of this thesis were: 
1. To investigate the association between self-reported respiratory symptoms and 
symptom score and mortality from all causes over 30 years and at different times 
during follow-up. 
2. To investigate the association between self-reported respiratory symptoms and the 
scores of such symptoms and mortality from OLD and pneumonia over 30 years. 
3. To investigate the association between self-reported respiratory symptoms and 
mortality from IHD and stroke over 30 years in a large population-based sample. 
4. To investigate the association between respiratory symptoms in the general population 
and the incidences of various types of lung cancer during the following 30 years, in 
separate time windows.  
 
 20 
LIST OF PAPERS 
This thesis is based on the following publications:  
1. Frostad A, Soyseth V, Andersen A, Gulsvik A. Respiratory symptoms as predictors of 
all-cause mortality in an urban community: a 30-year follow-up. J Intern Med 2006; 
259:520–529. 
2. Frostad A, Soyseth V, Haldorsen T, Andersen A, Gulsvik A. Respiratory symptoms and 
30-year mortality from obstructive lung disease and pneumonia. Thorax 2006; 61:951–
956. 
3. Frostad A, Soyseth V, Haldorsen T, Andersen A, Gulsvik A. Respiratory symptoms and 
long-term cardiovascular mortality. Respir Med 2007; 101:2289–2296.  
4. Frostad A, Soyseth V, Haldorsen T, Andersen A, Gulsvik A. Impact of respiratory 
symptoms on lung cancer, 30 year follow-up of an urban survey. Lung Cancer 
2008;60:22–30. 
 21 
MATERIAL AND METHODS 
Study population  
The study population was recruited from the First Asthma Oslo Study, a cross-sectional 
survey conducted in Oslo in 1972 to assess the age- and sex-specific prevalence of respiratory 
symptoms and OLD in the community and to establish a basis for studies of the natural 
history of OLD in the community [6]. The baseline survey has been described previously 
[6,100]. 
The population of Oslo, the capital of Norway, was 472 609 persons at the end of 1972 and 
comprised 12% of the total population of Norway. The sampling frame was an updated list 
from the Central Population Register of 340 252 persons aged 15–70 years living in Oslo on 1 
June 1972. From this population, a sample of 19 998 individuals were randomly selected. 
During November 1972, the selected persons received a postal questionnaire. The mailing and 
the processing of the data have been previously described [20]. 
Altogether, 17 690 persons returned the questionnaire [20], giving an overall response rate of 
89% (range, 85–93%). The response rate was highest for the 15–19-year age group and 
generally somewhat lower among men than women (Figure 2). The returned questionnaires 
are kept in the archives of the National Hospital in Norway. 
During autumn 1972, six of the respondents died and six emigrated. These 12 persons were 
excluded from the study, leaving 19 678 for the analyses. Eight persons were found to have 
lung cancer in autumn 1972 and were excluded from the analyses of incidence of lung cancer 
(paper 4). (See Figure 3.) 
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Figure 2. Response rates (%) of persons invited to participate in the First Asthma Oslo 
Study by sex and age group 
0
10
20
30
40
50
60
70
80
90
100
15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-70
Age-group (years)
%
Men
Women
 
 
Age and sex 
At 1 January 1973, the cohort consisted of 8147 men and 9531 women, representing 46% and 
54% of the respondents, respectively. The age distribution of the respondents is shown in 
Table 2.  
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Figure 3. Flow chart of inclusion of participants in the study 
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Table 2. Distribution of respondents by age and sex at 1 January 1973 
Age group (years) Men Women Total 
15–70 8 147 9 531 17 678 
15–19 640 661 1 301 
20–24 842 1 079 1 921 
25–29 1 142 1 184 2 326 
30–34 642 639 1 281 
35–39 556 609 1 165 
40–44 617 673 1 290 
45–49 688 778 1 466 
50–54 815 948 1 763 
55–59 827 1 042 1 869 
60–64 717 958 1 675 
65–70 661 960 1 621 
 
 
The Central Population Register of Statistics Norway  
Since 1964, all residents of Norway have had a unique 11-digit individual identification 
number containing their date of birth. Name, address and identification number are registered 
by the Central Population Register of Statistics Norway, which by law must be kept up to date 
[101]. This number simplifies the identification of individuals and is reliable; it allows 
linkage of the data with other, external sources. All deaths and emigrations of Norwegian 
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citizens are registered in the Central Population Register on the basis of the identification 
number.  
 
Questionnaire and variables used in the analyses 
In spring 1972, five chest physicians and one epidemiologist at the Department of Lung 
Diseases, National Hospital in Oslo, adapted a questionnaire from the 1966 update of the 
1960 British Medical Research Council Committee on Chronic Bronchitis questionnaire 
[102]. The adapted questionnaire consists of 39 questions on respiratory symptoms and 
physician-diagnosed pulmonary and cardiac disorders, on a single sheet. The Norwegian 
Respiratory Questionnaire is given in Appendix 1, with an English translation in Appendix 2. 
The validity of the questionnaire has been evaluated by lung function levels and bronchial 
responsiveness and found to be in crude agreement with the British Medical Research Council 
questionnaire [103,104]. 
 
Definitions of respiratory symptoms used in the study 
The questionnaire contained 11 questions on respiratory symptoms (Table 3), which were 
pooled into six symptom groups in paper 1, and four symptom groups in papers 2–4, and a 
symptom score described below.  
Cough symptoms 
Four questions concerned cough. Persons who gave an affirmative answer to at least one of 
the following questions were considered to have cough: “Do you usually cough or clear your 
throat in the morning?”, “Do you usually cough during the rest of the day?”, “When you 
cough or clear your throat, do you usually bring up phlegm?” and “Do you have cough for 3 
months or more altogether during a year?” 
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Long-lasting cough after a cold (paper 1) 
Long-lasting cough after a cold was defined as having cough and/or phlegm for more than 3 
weeks after a cold, once or several times, during the past 2 years.  
Wheezing (paper 1) 
Wheezing was defined as an affirmative answer to the question: “Have you ever had 
wheezing in your chest?” 
Attacks of breathlessness (paper 1) 
Persons were considered to have had attacks of breathlessness if they answered “Yes” to the 
question “Do you sometimes have attacks of breathlessness?”  
Asthma-like symptoms (papers 2–4) 
Asthma is a chronic inflammatory disorder and may therefore give different symptoms over 
time. Long-lasting cough after a cold can be a sign of hyperresponsiveness of the airways. 
Persons giving an affirmative answer to this question and to those on wheezing or attacks of 
breathlessness were regarded as having asthma-like symptoms. 
Moderate dyspnoea  
Moderate dyspnoea was considered to be present if an affirmative answer was given to at 
least one of the questions “Are you more breathless than other people of your age when 
walking uphill?” or “Are you breathless when you climb two flights of stairs at an ordinary 
pace?” and no affirmative answer to the questions regarding severe dyspnoea.  
Severe dyspnoea  
Severe dyspnoea was defined as present if an affirmative answer was given to at least one of 
the questions “Are you breathless when you walk on level ground at an ordinary pace?” or 
“Are you breathless when at rest?” 
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Table 3. Respiratory symptom groups and questions defining them  
No.a Question in 1972 questionnaire Respiratory 
symptom in our 
study, paper 1 
Respiratory 
symptom in our 
study, papers 2–4 
8 Do you usually cough and clear your throat in the 
morning? 
Cough  Cough symptoms 
9 Do you usually cough during the day?   
10 When you cough or clear your throat, do you 
usually bring up phlegm? 
  
11 Do you have cough for 3 months or more 
altogether during a year? 
  
12 During the past 2 years, have you had a cough 
and/or phlegm in connection with a cold for more 
than 3 weeks? 
Cold-induced 
long-lasting 
cough 
Asthma-like 
symptoms 
7 Do you have attacks of breathlessness? Attacks of 
breathlessness 
 
18 Have you ever had wheezing in your chest? Wheezing  
13 Are you more breathless than other people of your 
age when walking uphill? 
Moderate 
dyspnoea  
Moderate 
dyspnoea  
14 Are you breathless when you climb two flights of 
stairs at an ordinary pace? 
  
15 Are you breathless when you walk on level 
ground at an ordinary pace? 
Severe 
dyspnoea  
Severe dyspnoea  
16 Are you breathless when at rest?   
a 
Number of question in Norwegian Respiratory Questionnaire 
 28 
One or more affirmative answer to a single question was enough for inclusion in one 
symptom group. Thus, persons who reported several respiratory symptoms could be classified 
in a maximum of three of four symptom groups (Figure 4). 
 
Figure 4. Distribution of respiratory symptom groups in the cohort of 17 678 persons 
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Symptom score 
A symptom score ranging from 0 to 11 was defined as the sum of affirmative answers to 11 
equally weighted respiratory symptom questions. The scores were then arbitrarily grouped as 
0 (no respiratory symptoms), 1–3, 4–6 and ≥ 7 respiratory symptoms. No overlap was present. 
The distribution of number of symptoms reported is shown in Figure 5.  
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Prevalence of respiratory symptoms at baseline 
No respiratory symptoms were reported by 49% of the respondents. Of the 8950 persons 
(51%) who reported symptoms, 4311 were men and 4639 women (Table 4). The most 
frequent symptom groups reported were cough and asthma-like symptoms (Figure 4). The 
majority of the symptomatic individuals reported three or fewer respiratory symptoms (Figure 
5).  
 
Figure 5. Distribution of number of symptoms reported in the cohort of 17 678 persons 
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Smoking habits 
Baseline smoking status was divided into five groups. Persons who had never smoked or had 
smoked daily for less than 1 year were classified as never having smoked. Persons who had 
smoked daily for more than 1 year and had stopped smoking for more than 1 year before the 
survey were defined as former smokers. Current smokers were defined as persons who had 
smoked daily for more than 1 year, including those who had stopped smoking less than 12 
months before the survey. Tobacco consumption was measured in grams per day, one 
cigarette being considered equivalent to 1 g of tobacco. Consumption was scored as < 10, 10–
19 and  20 g of tobacco per day. This categorization of smoking habits was used in all four 
papers.  
Persons were classified as having unknown smoking habits (total, 262 persons) when they did 
not answer the questions about smoking history or did not give quantitative information on 
their tobacco or cigarette consumption.  
 
 
Occupational exposure of the airways 
With regard to occupational exposure to air pollution, respondents were divided into two 
groups depending on whether they answered “Yes” or “No” to the question: “Are you or have 
you been exposed to dust, fumes or noxious vapours (gases) in your work?” Among the 3138 
(18%) respondents who answered “Yes” to this question, 70% were men.  
 
Other variables 
Information about allergy in the family (question 7 of the Norwegian Respiratory 
Questionnaire), own allergy (questions 25–27) and physician-diagnosed lung diseases 
(asthma, bronchitis, emphysema and other lung diseases, questions 28–33) and heart 
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diseasees (myocardial infarction, angina pectoris, heart failure and other heart diseases, 
questions 34–37) were also available from the questionnaire. The use of some of these 
variables is described under “Statistical analyses”. 
 
Follow-up  
Observation began on 1 January 1973, at which time 17 678 respondents (8147 men and 9531 
women; response rate, 89%) were alive and living in Norway. They were followed-up until 
date of death (papers 1–3), lung cancer diagnosis (paper 4), emigration or 31 December 2002, 
whichever occurred first. The follow-up included 441 117 person–years.  
 
End-points used in the study 
When reporting diagnoses, physicians in Norway used the 8th revision of the International 
Statistical Classification of Diseases, Injuries and Death (ICD) during the period 1970–1985, 
the 9th revision up to 1995, and the 10th revision since 1996.  
The analyses were based on mortality from all causes, OLD, pneumonia, IHD and stroke 
given as the underlying cause of death (Table 5). For mortality from OLD, we also analysed 
the mortality when this was given as a contributory cause of death. In analysing lung cancer 
incidence, we used the first occurrence only for persons who had more than one diagnosis of 
lung cancer.  
The sources for the end-points of this study were the Death Register in Statistics Norway and 
The Cancer Registry of Norway. For the present study, answering and returning the 
questionnaire was considered to represent informed consent. The South Norwegian Regional 
Committee for Medical Research Ethics approved the protocol. The Data Inspectorate and the 
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Norwegian Directorate of Health and Social Services granted permission to perform the 
study.  
 
Table 5. ICD codes for diagnoses used in the analyses, by period [105,106] 
End-point diagnosis 1973–1985 (ICD8) 1986–1995 (ICD9) 1996–2002 (ICD10) 
All causes  000–999 001–999 A00–Z99 
Obstructive lung disease 491–493, 518  490–494, 496 J40–J47 
Pneumonia 480–486  480–486  J12–J18 
Ischaemic heart disease 410–414 410–414 I20–I25 
Stroke 430–438 430–438 I60–I69 
Lung cancer 162 162 C33–C34 
 
 
Death Register in Statistics Norway 
Since 1951, Norway has prepared official statistics on causes of death in accordance with the 
ICD as recommended by the World Health Organization [107]. The statistics cover all 
persons registered by the Central Population Registry as living in Norway at the time of 
death.  
Whenever a death occurs, a certificate is issued by a physician and sent to Statistics Norway. 
Deaths registered on the basis of medical death certificates are matched with deaths registered 
in the Central Population Register. Additional information is routinely obtained from The 
Cancer Registry of Norway, the Medical Birth Registry of Norway and Statistics Norway, 
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statistics on road traffic accidents and the results of autopsies from hospitals and forensic 
laboratories. This process ensures the completeness of the data. The certificate always gives 
the underlying cause of death and, if appropriate, contributing causes. The underlying cause is 
defined as the disease or external cause of injury that started the chain of events leading to 
death. The contributory cause of death may be a disease that followed the underlying cause 
and that might have contributed to death [108].  
 
The Cancer Registry of Norway 
The Cancer Registry of Norway has systematically collected notifications on cancer for the 
Norwegian population since its inception in 1952 and is considered very close to complete 
from 1953. The reporting of cancer has been compulsory since a directive was issued by the 
Ministry of Health and Social Affair in 1951.  
The reporting system is based on pathology and cytology reports, clinical records and death 
certificates. Information is collected from clinicians and pathologists, as well as from the 
administrative patient discharge register and cause of death register. Nominal reporting of 
cancer cases is compulsory for physicians and includes the identification number. The 
incidence registry is updated continuously with information on new cases and new 
information on cases diagnosed previously. The Registry‟s in-house coding and classification 
system adheres to certain international standards [107,109].  
 
Processing the data file 
Data from the First Asthma Oslo Survey were initially registered on paper forms and 
subsequently entered into a data file. The processing of this data file, including testing for 
inconsistencies, has been previously described [20]. When the data file was checked against 
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the Central Population Register in 2002, 52 persons were found not to have valid 
identification number. The original questionnaires in the archives of the National Hospital in 
Oslo were searched manually and the personal identification numbers corrected.  
For the outcome variable, the personal identification numbers in this cohort were linked to the 
Death Registry in Statistics Norway and The Cancer Registry of Norway. Persons for whom 
answers on specific items were missing were excluded from the relevant analysis.  
 
Statistical analyses 
The statistical analyses were performed in two steps. First, we calculated the crude mortality 
rate (MR), as the number of deaths or lung cancer cases per 100 000 person–years in the 
study. Then, the association between respiratory symptom category and the end-point, 
mortality or lung cancer was estimated from a Cox proportional hazard regression model 
[110]. Multiple regression analyses permit inclusion of different variables suspected of being 
associated with the outcome variable. All explanatory variables were adjusted for each other, 
ensuring that the results were not confounded by other known factors given in the 
questionnaire.. The estimates from the Cox proportional hazard regression model were 
expressed as a hazard ratio (HR) with 95% confidence intervals (CIs). If the HR was greater 
than 1 and the 95% CI did not include 1, the persons associated with the exposure variable 
(respiratory symptom) were considered to have a significantly increased risk for the outcome 
variable.  
All-cause mortality, cause-specific mortality and incidence of lung cancer associated with 
each symptom group were compared with those among persons who had not reported any 
respiratory symptoms. As mortality and developing lung cancer were more strongly 
 37 
associated with age than time in the study or calendar time, age was used as the underlying 
time scale [111,112]. 
The proportional hazard assumption of the Cox model was checked graphically and with a 
test based on Schoenfeld‟s residuals on partial likelihood [113,114].  
If analyses of the univariate associations between the end-point of interest and specific 
covariates revealed an association between the covariate and the outcome at p ≤ 0.05, the 
covariate was included in an initial multivariate model as a possible confounder. Then, a 
multivariate model was constructed for each symptom group, and each model was reduced by 
backwards elimination. Variables were removed from this model if the regression coefficient 
between mortality or lung cancer incidence and symptom group was altered by less than one 
standard error. Variables removed in this way were information about allergy in the family 
and own allergy.  
Product terms were constructed between respiratory symptoms and smoking habits and 
between respiratory symptoms and occupational exposure to air pollution in order to 
investigate effect modification on the end-point by these variables. No such effect 
modification was found. Smoking habit and exposure to air pollution were included as 
covariates. Separate analyses were conducted for men and women. 
Information about OLD, IHD and other pulmonary and heart disorders were considered steps 
in the causal chain between respiratory symptoms and mortality from all causes and cause 
specific mortality or incidence of lung cancer and were therefore not treated as possible 
confounders [115]. As OLD and IHD are significant predictors of early death in long-term 
follow-up, we also performed the analyses after excluding persons with these physician-
diagnosed diseases.  
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As information on whether an autopsy had been performed was available only for deaths after 
1986, we investigated the association between respiratory symptoms and mortality from 
autopsy-based cause of deaths for the period 1986–2002 separately.  
Wald‟s test for trend was performed with symptom score and grams of tobacco smoked as 
continuous variables.  
We also investigated the association between respiratory symptoms and mortality in separate 
10-year periods of follow-up. All analyses were performed with STATA-9 for Windows 
[116].  
Our estimate of the association between respiratory symptoms and all-cause mortality was 
unchanged when we adjusted for smoking habits in two different ways: by consumption in 
gram tobacco per day at baseline or in pack–years smoked until that day. We used tobacco 
consumption in gram tobacco per day at baseline in the analyses. 
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MAIN RESULTS 
Paper 1: Respiratory symptoms as predictors of all-cause mortality in an urban 
community: a 30-year follow-up 
During follow-up, 6710 (38%) persons, 3380 men and 3330 women, died.  
The adjusted HR for mortality from all causes varied from 1.36 (95% CI, 1.25–1.48) for 
cough symptoms to 2.46 (2.13–2.85) for severe dyspnoea among men; the corresponding HRs 
among women were 1.28 (1.16–1.40) and 1.52 (1.31–1.75), in comparison with asymptomatic 
subjects. The HRs for all-cause mortality in persons with 1–3, 4–6 and 7 or more symptoms 
were 1.20, 1.60 and 2.53 for men and 1.14, 1.47 and 1.84 for women. The risk for mortality 
increased significantly with increasing number of symptoms reported. In the third decade of 
follow-up, 1993-2002, the HR for mortality from all causes was still significantly higher for 
persons who reported respiratory symptoms than those without symptoms. 
The positive association between respiratory symptoms and mortality was observed in 
persons with and without cardiopulmonary diseases.  
 
Paper 2: Respiratory symptoms and 30-year mortality from obstructive lung disease 
and pneumonia 
Out of a total of 6710 deaths recorded in the cohort, 582 were due to respiratory disease as the 
underlying cause of death. Obstructive lung disease accounted for 250 (43%) deaths, 
pneumonia for 293 (50%) and other lung diseases for 39 (7%) of all deaths due to respiratory 
disease.  
The HR for mortality from OLD varied from 4.0 (95% CI, 2.4–6.5) for cough to 9.6 (5.1–
18.3) for severe dyspnoea in men and from 5.1 (2.3–11.3) for moderate dyspnoea to 13.0 
(6.0–28.3) for severe dyspnoea in women. The symptom score was strongly predictive of 
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death from OLD, in a dose–response manner, from 2.3 to 13.6 in men and from 3.4 to 21.5 in 
women. 
No significant association was found between groups of respiratory symptoms and mortality 
from pneumonia. The symptom score did not significantly increase the HR for this end-point, 
except among women who reported more than seven symptoms.  
The HR for mortality from OLD decreased during follow-up for all respiratory symptoms in 
both sexes, but was still significantly increased in the third decade, except among men 
reporting severe dyspnoea. The HR in the third decade varied from 2.5 (1.3–4.8) to 3.0 (1.2–
7.3) for men and from 5.0 (1.7–14) to 6.7 (2.7–16) for women, for the four symptom groups.  
 
Paper 3: Respiratory symptoms and long-term cardiovascular mortality 
Of a total of 6710 deaths, 2881 were recorded as due to cardiovascular disease as the 
underlying cause during 1973–2002. Ischaemic heart disease accounted for 1572 (55%), 
stroke for 653 (23%) and other circulatory diseases for 656 (23%) of all deaths due to 
circulatory disease.  
The adjusted HRs for mortality from IHD in men varied from 1.3 (1.1–1.5) for cough 
symptoms to 3.0 (2.3–3.8) for severe dyspnoea. The corresponding figures for women were 
1.2 (1.0–1.5) and 1.9 (1.4–2.5). The symptom score was associated with death from IHD, in a 
dose–response manner. The HR for mortality from stroke varied from 1.0 to 2.3 in men and 
from 1.1 to 1.5 in women for the symptom groups, but was significant only for men reporting 
severe dyspnoea and for women reporting moderate dyspnoea. For all respiratory symptoms, 
the excess risk for cardiovascular mortality decreased during follow-up, but mortality from 
IHD was still significantly increased during the last decade. 
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Paper 4: Impact of respiratory symptoms on lung cancer: 30-year follow-up of an urban 
population 
Lung cancer was diagnosed in 352 persons (228 men and 124 women) during follow-up. 
Among these, 71% had reported any respiratory symptoms at baseline; cough symptoms and 
asthma-like symptoms being reported most often (59% and 51%, respectively).  
We found a significant positive association between the incidences of lung cancer and cough 
symptoms, with adjusted HRs (95% CI) of 1.4 (1.0–1.9) and 1.7 (1.0–2.7) for men and 
women, respectively. The association between the incidence of lung cancer and asthma-like 
symptoms was significantly positive among women, 1.7 (1.1–2.7), and among men reporting 
dyspnoea when walking uphill, 1.7 (1.1–2.5). The relative risk for lung cancer increased with 
the number of symptoms reported; it was strongest for the first decade and decreased with 
duration of follow up.  
The association between respiratory symptoms and lung cancer was almost unchanged after 
exclusion of 3653 persons with physician-diagnosed asthma, bronchitis or emphysema. 
Additionally, when the start of follow-up was set with a 1-year delay (1974), the results still 
showed an increased risk for lung cancer among persons who had reported respiratory 
symptoms when compared with those who had not reported such symptoms. 
Of the 352 cases of lung cancer diagnosed in the cohort, 329 (93%) were histological verified. 
Small-cell lung cancer was present in 78 persons, squamous-cell carcinomas in 87, 
adenocarcinoma in 89 and other non-small-cell carcinomas in 75 persons. The increased risk 
for lung cancer with increasing number of respiratory symptoms reported was more 
pronounced for non-small-cell lung cancer than for small-cell lung cancer.  
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DISCUSSION 
Methods  
Study design 
The research questions that initiated this study were: “Are respiratory symptoms risk factors 
for early death, and are they risk factors for development of lung cancer during the next 30 
years in comparison with persons without respiratory symptoms?” and “Is there any reason to 
worry when a person reports symptoms in the respiratory tract over some time?” To answer 
these questions, a longitudinal design was chosen in a historical cohort study [117].  
Large cohorts are needed to acquire a sufficient number of cases for the analysis of cause-
specific mortality and incidence of lung cancer. The strength of this population-based study is 
the random selection of persons, the large number of respondents and the long follow-up, 
which resulted in 441 000 person–years. No other published population-based study has 
included so many men and women and analysed so many respiratory symptoms as predictors 
of cause-specific mortality and lung cancer incidence. Because of the availability of the 
unique 11-digit personal identification number used in Norway and because Statistics Norway 
and The Cancer Registry of Norway are based on compulsory recording of all deaths and new 
cases of cancer, respectively, among residents in Norway, the estimates are not distorted by 
incomplete follow-up [109,118].  
 
Statistical methods 
The cohort consisted of nearly 20 000 persons, of whom 17 678 answered and returned the 
questionnaire. Of the respondents, about 50% reported no respiratory symptoms, and they 
were therefore used as the reference group in our analysis. We chose a traditional 
epidemiological method in which we separated the data into different groups and compared 
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the crude MR and crude incidence rates (IR) of the groups. We chose the Cox regression 
model for all analyses in order to take into account the exact time to the event and to allow 
censoring of data and adjustment for confounding [119]. 
 
Validity of results 
We found that respiratory symptoms are risk factors for all-cause mortality, cause-specific 
mortality and for incidence of lung cancer. Two questions arise in the interpretation of the 
results: “Do our results give the correct relation between respiratory symptoms and the 
outcome of the study (internal validity)?” and “Can our results be generalized to the broader 
population (external validity)?” 
 
Internal validity 
Internal validity, or internal lack of systematic error, can be defined as the validity of the 
inferences drawn pertaining to the population being studied [115]. The main limitations of 
internal validity are selection bias, information bias and confounding. 
Selection bias is distortion that can result from the sampling procedure or from factors that 
influence participation in the study. Our participants were selected randomly, and the 
response rate was high, which reduces the possibility of selection bias. Additionally, the 
comparison group, those individuals without respiratory symptoms, was an internal group 
within the cohort. The groups being compared were thus as similar as possible with respect to 
other factors that might be related to the diseases, except respiratory symptoms. This reduces 
selection bias.  
Information bias involves misclassification of the exposure or outcome of persons in the 
study and results in differential accuracy of information between comparison groups [115]. 
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With any diagnostic test or procedure, there is a chance of error, and this is also true for 
mailed questionnaires. Error can occur if persons who have respiratory symptoms answer that 
they do not, or vice versa. This is commonly called misclassification or reporting error. 
Misclassification can be differential or non-differential, depending on how it is linked to the 
outcome. 
Differential misclassification occurs when a systematic error links the exposure (symptoms) 
and outcome [115]. For example, if there is error in reporting respiratory symptoms for those 
persons who later become ill and die. In view of the long follow-up, this seems unlikely.  
Non-differential misclassification results when the inaccuracy occurs in categorization of 
participants by exposure or outcome status and occurs in similar proportions of each study 
group. In most instances, non-differential misclassification of exposures will produce a bias 
towards the null value, corresponding to a hazard ratio of 1.0 [115]. 
Using the same questions on respiratory symptoms from the Norwegian Respiratory 
Questionnaire, Eagan et al. found that the remission rate over 11 years varied from 45% for 
dyspnoea to 58% for chronic cough [56]. Our study design did not allow us to verify the 
persistence of respiratory symptoms. Despite the reported variation in individual respiratory 
symptoms, we found a strong association between symptoms reported in 1972 and the various 
end-points 30 years later.  
The major source of uncertainty with regard to cause of death is physicians‟ reporting of 
diagnoses on death certificates [108,120,121]. In addition, the coding of diagnoses has 
changed, and three different ICD systems were used during the period of the study. In a study 
of deaths from active tuberculosis, considerable error was found in the reporting of diagnosis: 
in one third of deaths the diagnosis was under-reported and in one third it was over-reported, 
resulting in a fairly correct mortality rate [122]. 
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One of the gold standards for determining cause of death is autopsy. If autopsies were 
conducted before 1986, they were not mentioned on the death certificates. Autopsy-verified 
diagnoses during the period 1986–2002 varied in this cohort from 7% for pneumonia to 32% 
for IHD (Table 6). Our analysis based on autopsy-recorded causes of death gave similar 
results to those obtained with all death certificates in this period, thus strengthening our 
conclusions. The diagnosis of lung cancer was obtained from The Cancer Registry of Norway 
and was histologically or cytologically verified in more than 90% of cases.  
 
Table 6. Cause-specific deaths and percentages autopsied, 1986–2002 
Cause of death No. of deaths Autopsy as source of 
diagnosis (%) 
All causes 6 710 15 
Ischaemic heart disease 1 572 32 
Stroke    653 11 
Obstructive lung disease    250 17 
Pneumonia    293   7 
 
Confounding: A confounder is a variable associated with both the exposure and the outcome. 
It should not be an intermediate step in the pathway between exposure and disease [115]. We 
defined the information about physician-diagnosed respiratory and/or cardiovascular disease 
as a possible variable in this pathway. 
Smoking might be a strong confounder of the association between respiratory symptoms and 
outcome. Smoking habits were recorded only at inclusion into the survey in 1972 and 
probably changed during follow-up. Cohort studies conducted in Norway in 2001 by Eagan 
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and colleagues and in 2005 by Stavem and colleagues showed, however, that twice as many 
persons had stopped smoking than had started smoking or had started again during follow-up 
periods of 11 and 27 years [16,123]. Additionally, the total proportion of daily smokers 
among Norwegian men and women decreased during the follow-up period (Figure 1), and 
some of the respondents in our study might have stopped smoking in response to the 
Norwegian Tobacco Act and to educational programmes on smoking and health. Other 
studies have shown that smoking cessation reduces the relative risk for death and lung cancer 
when compared with continuation of smoking [124,125]. We were unable to take into account 
in our analyses changes in respiratory symptoms during follow-up among persons who quit 
smoking. If we had taken into account remission of respiratory symptoms after quitting or 
reducing smoking [56], our analyses would probably be underestimates rather than 
overestimates of the relation between symptoms and outcome. We found no modification of 
the relation between symptoms and outcome by smoking habit. Thus, the presence of 
respiratory symptoms increased cause-specific mortality and lung cancer incidence similarly 
among smokers and non-smokers. A similar result was found by Rosengren et al. [80].
  
Despite adjustment for smoking habits at baseline, some residual confounding by smoking 
could remain due to changes in smoking habits during follow-up. We found, however, that the 
associations between respiratory symptoms and the outcome variables were approximately 
the same when analysed for persons who had never smoked and when adjusted for smoking 
habits (Table 7). 
An additional limitation of our study is the lack of information on other potential 
confounders, such as lung function, socioeconomic status, physical activity and other risk 
factors. Lung function is well known to be a predictor of mortality and lung cancer 
[85,90,126]; however, Knuiman et al. [85] and Vestbo et al. [127] found that dyspnoea is
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related to mortality from all causes independently of lung function. 
Stavem et al. [128] followed an occupational cohort of middle-aged men for 26 years and 
found that phlegm and breathlessness were associated with all-cause mortality, even after 
adjustment for physical fitness, lung function, known cardiovascular disease and smoking. 
The association was not significant for mortality from cardiovascular disease, as the cohort 
consisted of only 1999 men [128]. Juosilahti et al. [129] found in a study of nearly 20 000 
Finnish men and women followed for 13 years that symptoms of chronic bronchitis (i.e. 
cough with phlegm 3 months or more during a year) predicted risk for death from 
cardiovascular disease independently of other known major cardiovascular risk factors[129].  
Factors other than tobacco smoking, such as occupational exposure to asbestos, metals such 
as nickel, arsenic and cadmium, radon and ionizing radiation, are known to increase the risk 
for lung cancer [130]. In our study, however, occupational exposure to dust and gases did not 
appear to increase the risk for lung cancer, and, after adjustment, such exposure was 
significantly associated only with mortality from OLD in men. A Norwegian population-
based study showed that both men and women tended to leave jobs entailing exposure to 
pollutants more often than jobs with no such exposure [131]. This might explain the 
unexpectedly weak association between occupational exposure to dust and gases and early 
death and lung cancer incidence. This could also be because the question about occupational 
exposure was not specific, and our study had too little power to establish any association 
between occupational exposure and mortality or lung cancer risk.  
External validity  
External validity (or generalizability) can be defined as the ability to generalize from 
observations in a community to people outside the study population [117]. The prevalences of 
respiratory symptoms and smoking in our study population were similar to those in other 
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populations studied in Norway [7,13,16,27,132,133]; however, we saw fewer deaths from 
pneumonia in our cohort than in the populations of Oslo and Norway (Table 8). This may be 
because our cohort excluded people over 70 years at baseline. The numbers of deaths from 
other causes among inhabitants of Oslo and Norway correlated well with those in our cohort 
[105]. Even though the response rate was somewhat lower among persons aged 20–34 years 
and lower for men than women, the overall rate was very high. The difference is small and 
should not prevent the generalizability of our results to the Norwegian population.  
 
Table 8. Deaths from all causes, obstructive lung disease, pneumonia, ischaemic heart 
disease, stroke and lung cancer in the populations of Norway and Oslo and in our cohort 
in 1973–2002 [105]  
Cause of death Norway, all ages Oslo, all ages Our cohort, aged 15–70 
years in 1972 
No. % of all deaths No. % of all deaths No. % of all deaths 
All 1 336 192 100 185 370 100 6 710 100 
Obstructive lung 
disease  
34 708 3 5 543 3 250 4 
Pneumonia  81 258 6 12 909 7 293 4 
Ischaemic heart 
disease  
317 221 24 42 381 23 1 572 23 
Stroke 165 210 12 21 543 12 653 10 
Lung cancer  41 926 3 6 998 4 318 * 5 
* From reference [134]
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Results 
This study showed that respiratory symptoms reported at one time by nearly 18 000 persons 
in Oslo, Norway, were significant predictors of mortality from all causes, obstructive lung 
disease and ischaemic heart disease in the subsequent 30 years, after adjustment for age, 
smoking habits and occupational exposure. Weaker association were found for mortality from 
pneumonia and stroke and for the incidence of lung cancer.  
 
Associations between respiratory symptoms and the outcome variables 
Cough symptoms 
There are sex-related differences in the perception and reporting of respiratory symptoms: 
cough and sputum production are less commonly reported by women than men [27,135]. 
Among coughers, women report a higher prevalence of non-productive cough than men 
[40,136]. In a study of patients with chronic cough, women had a more sensitive cough reflex 
to both capsaicin and citric acid [137].  
We pooled all cough symptoms, with and without phlegm, into one group. Cough symptoms 
were reported more often by men than women, both as individual symptoms and as a group. 
Despite these differences, we found no significant difference by sex in the association 
between cough symptoms and all-cause or cause-specific mortality or the incidence of lung 
cancer. 
A positive association has been reported between chronic mucus hypersecretion (chronic 
cough with phlegm > 3 months a year) and mortality from COPD in several studies, most of 
which were conducted in occupational settings [126,138]. In a population-based Danish 
study, a significant association was found between chronic mucus hypersecretion and 
mortality from OLD, adjusted for lung function [79]. Although we had no information about 
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lung function, we had information on reported physician-diagnosed asthma, bronchitis or 
emphysema. In agreement with a Swedish study, we consider that there is an accumulation of 
individuals with low lung function among those with already diagnosed OLD [9]. In 
excluding those persons, we excluded most individuals with very low lung function.  
In the present study, cough symptoms were significantly associated with increased mortality 
from IHD. Our findings are partly in agreement with those of smaller population-based 
studies [80,82,85]. Todd et al. [82] found a positive association with chronic cough in both 
sexes[82], while Knuiman et al. [85] found a significant association only for men.  
We found a positive association between cough symptoms and mortality from stroke, 
although the association was not significant. Two other studies showed non-significant 
negative associations between chronic cough and mortality from stroke in both sexes [82,85].  
Vestbo and colleagues [8] found a strong positive relationship between cough and the 
incidence of respiratory tract cancer in a cohort of 876 middle-aged Danish men, with an age- 
and smoking-adjusted HR of 2.5[8]. Our findings are in closer agreement with those of cohort 
studies analysing the association between respiratory symptoms and mortality from lung 
cancer [82,93]. These studies included both men and women, and large groups were followed 
for about 12 years. With a reported ratio of mortality:incidence for lung cancer of 9:10 [139], 
we can assume that in our study with a 30-year follow up, there is a vanishing difference 
between the risk for developing lung cancer and the risk for dying from lung cancer.  
Like us, Peto and colleagues found a moderate relation between mucus hypersecretion in men 
and mortality from lung cancer, and they showed that the relation between phlegm production 
and mortality from lung cancer remained after adjustment for FEV1 [140]. Airway irritation 
that causes productive cough and neoplasm both occur predominantly in the large airways. 
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Asthma-like symptoms 
Asthma-like symptoms can include wheezing, attacks of breathlessness and other symptoms 
of bronchial hyperresponsiveness such as long-lasting cough after a cold. Wheezing was 
found to increase mortality from all causes among men in Great Britain and Australia [81,85] 
and among women in Poland [83], whereas in the United States no association was found 
[84]. Our study showed that wheezing is a significant risk factor for mortality from all causes 
in both men and women. This is probably due to the greater power of our study, with a large 
number of person–years under observation. 
The mortality risk associated with cold-induced long-lasting cough is a new observation. The 
association between attacks of breathlessness and mortality was reported by Krzyzanowski et 
al., who, like us, found a greater increase in risk among men than women [83]. 
We found little difference in the association between mortality from all causes and wheezing, 
attacks of breathlessness and long-lasting cough after a cold. When we defined asthma-like 
symptoms as an affirmative answer to question 12, 17 or 18, (see Table 3), the significantly 
increased risk remained for both sexes. 
A study in Busselton, Australia, showed that persons who reported wheezing had an increased 
risk for death from respiratory disease in general [85]. A French study showed that attacks of 
breathlessness and wheezing were significantly associated with death from COPD, with a 
relative risk of 3.5 [87]. In our study, asthma-like symptoms resulted in a higher HR for 
mortality from OLD than in the French study[87]. Studies in France and Denmark showed 
that persons with asthma or symptoms of asthma had a 20–40% increased risk for death from 
cardiovascular disease than those without such symptoms [87,92]. We have no explanation 
for the finding that asthma-like symptoms (after adjustment for other respiratory symptoms) 
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were associated with a lower risk for stroke in women but not in men. This observation 
should be confirmed in future population-based studies.  
In agreement with a study of hospitalized asthma patients in Sweden [98], we found a 
significantly increased risk for lung cancer among persons with physician-diagnosed asthma 
bronchiale. Additionally, as the prevalence of diagnoses of asthma and asthma-like symptoms 
in adults has increased [18], we can assume a future increase in the incidence of lung cancer, 
given the same smoking habits. The association between asthma-like symptoms and lung 
cancer incidence did not change after exclusion of persons with physician-diagnosed OLD.  
 
Dyspnea symptoms 
Shortness of breath was reported more frequently by women than men in Norwegian 
population-based studies [6,16]. In our study, the association between severe dyspnoea and 
mortality from all causes was significantly higher among men than women. The association 
between dyspnoea and the other end-points of the study, cause-specific mortality and 
incidence of lung cancer, was not, however, affected by sex. 
Dyspnoea on exercise is a frequent presenting symptom of both lung and heart disease. It is 
therefore to be expected that a considerable proportion of persons who reported dyspnoea at 
baseline had heart or lung disease, with a serious prognosis. It is thus not surprising that the 
relative mortality risk decreased during follow-up. The long-term survivors who had reported 
dyspnoea might have had conditions with a more favorable prognosis, such as poor physical 
fitness, overweight or hyperventilation. After excluding those individuals with physician-
diagnosed heart or lung disease, we still found an association between dyspnoea and mortality 
from all causes, OLD, IHD and stroke.  
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Our finding of an association between dyspnoea and total mortality is in agreement with that 
of an occupational cohort study of Norwegian men followed for 26 years which showed an 
increased risk for death from all causes even after adjustment for physical fitness, smoking 
habits and lung function [128]. Our finding of a significant association between dyspnoea and 
mortality from OLD is in agreement with those of population-based surveys [80,81,85]. Our 
finding of increased risks for death from IHD and stroke among men and women who 
reported dyspnoea confirms previous results in men [80,85]. 
 
Respiratory symptom score 
The number of symptoms present is an estimate of the burden of respiratory symptoms. An 
earlier Norwegian study showed that persons with respiratory symptoms had poorer lung 
function than persons without symptoms [103], independently of the presence of disease with 
spirometrically verified airway obstruction [141]. Our study shows that an increased number 
of respiratory symptoms increases both overall and cause-specific mortality from OLD and 
IHD, after adjustment for age, smoking habits and occupational exposure. The number of 
symptoms may be a simple indicator of the severity of the underlying pathological entity in 
the airway in both men and women.  
  
Possible mechanisms for the associations between respiratory symptoms and earlier death 
and lung cancer 
In recent years, there has been increasing focus on the possible role of inflammation in both 
malignant and non-malignant disease. Respiratory symptoms might be markers of an acute or 
chronic inflammatory process in the lungs and airways and might be present before other 
clinical manifestations.  
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Obstructive lung diseases are inflammatory diseases [37,142], and persons with physician-
diagnosed OLD without respiratory symptoms can be satisfactorily treated with 
bronchodilators and anti-inflammatory drugs and be cured [37,143]. In a 3-year controlled 
clinical trial, patients with COPD treated with long-lasting adrenergic β2-agonist and inhaled 
steroids showed a tendency to reduced mortality [144]. In our study, persons with physician-
diagnosed OLD had a significantly increased risk for mortality from all causes; however, 
persons with a previous history of OLD but no respiratory symptoms at baseline had no 
increased risk for mortality (data not shown). This finding supports the hypothesis that 
respiratory symptoms might be an indicator of chronic inflammatory processes in the airways 
and thereby of a risk for earlier death due to respiratory and cardiovascular diseases and the 
development of lung cancer.  
Sin and Man [145] postulated that persistent pulmonary inflammation promotes release of 
pro-inflammatory mediators and cytokines into the circulation and that the mediators 
stimulate production and release of acute-phase proteins and inflammatory cells, leading to a 
state of low-grade systemic inflammation. High-sensitivity C-reactive protein is the best 
studied inflammatory marker. Airway obstruction is associated with increased blood levels of 
systemic inflammatory markers like C-reactive protein and fibrinogen [146-148]. The 
systemic inflammation, in turn, may affect blood vessels, in particular promoting 
atherosclerotic plaque instability and rupture. C-Reactive protein has been shown to predict 
myocardial infarction, stroke and vascular events [149-154]. Statins seem to attenuate 
inflammatory risk and have been shown to improve survival after exacerbation of OLD 
[155,156].  
Thus, as systemic inflammation may have an important role in human cancer development in 
general, the plasma C-reactive protein level is a potential marker of increased cancer risk 
[157]. It has been proposed that chronic inflammation in the lung can stimulate cell 
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proliferation and growth, leading to lung cancer [158,159]. Although cigarette smoking may 
explain 80–85% of lung cancers in the Nordic countries [94], several studies have indicated 
an association between lung cancer and non-malignant pulmonary diseases such as COPD, 
pneumonia and lung tuberculosis, even in non-smokers and after adjustment for smoking 
habits [95-98,160-162].  Moreover, this risk increases inversely with level of pulmonary 
function expressed as FEV1 [99].  
The associations between respiratory symptoms and lung function [163-165] and between 
lung function and several causes of death are well known [79,85,90,166]. Our study does not 
elucidate why respiratory symptoms increase the risk for cause-specific mortality and lung 
cancer or why self-reporting of such symptoms at any time has such a long-lasting effect. We 
have nevertheless shown that common respiratory symptoms are important predictors of 
diseases over 30 years.  
Recording symptoms is simple, cheap and applicable to most people. Awareness of 
respiratory symptoms is important in clinical practice for detecting underlying diseases. This 
study supports the hypothesis that modulating pulmonary inflammation might favourably 
affect later development of diseases that could lead to earlier death or lung cancer. This 
conclusion must, however, be confirmed in controlled clinical trials. 
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MAIN CONCLUSIONS 
1. Respiratory symptoms were significantly associated with mortality from all causes over 
30 years. The relation between respiratory symptoms and all-cause mortality increased 
with the number of symptoms and decreased during follow-up, but was still increased 
during the last decade of follow-up. 
2. We found a strong, positive association between respiratory symptoms and 30-year 
mortality from OLD. The risk of mortality from OLD increased strongly with the number 
of symptoms and was greater than 10 for people who reported seven or more respiratory 
symptoms when compared with persons without symptoms. The association between 
respiratory symptoms and mortality from pneumonia was weak and not significant.  
3. We found a significant, positive association between respiratory symptoms and 30-year 
mortality from IHD. A weak positive association was found between respiratory 
symptoms and mortality from stroke 30 years later. 
4. An increased risk for the development of lung cancer was observed in both men and 
women reporting cough symptoms, women reporting asthma-like symptoms and men 
reporting dyspnoea when walking uphill. The association was strongest during the first 
decade and decreased with duration of follow-up, but was still increased, although not 
significantly, during the last decade. The risk increased with the number of symptoms 
reported at baseline, to a greater extent for non-small-cell lung cancer than for small-cell 
lung cancer.  
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PERSPECTIVES AND RESEARCH QUESTIONS 
The present study has contributed importantly to epidemiological research as it presents 
estimates for the predictive value of many respiratory symptoms for cause-specific mortality 
and the incidence of lung cancer in a large population of adults followed over 30 years. These 
findings show that we must take respiratory symptoms seriously.  
Our findings allow us to suggest that increasing awareness of respiratory symptoms can lead 
to diagnoses that will necessitate treatment to reduce the symptom load. Fewer respiratory 
symptoms will reduce morbidity and mortality over time and consequently increase quality of 
life and facilitate calculation of health costs.  
 
This thesis has answered some research questions, but it has also raised several new 
questions, which should be answered in future studies.  
 Was the cause-specific mortality among persons who did not return the questionnaire 
different from that of persons who returned a filled-in questionnaire? 
 The accuracy of the information about OLD, pneumonia, stroke and IHD on death 
certificates completed by physicians should be established by comparison with 
autopsy results. 
 The association between respiratory symptoms and cause-specific mortality should be 
examined after adjustment for lung function and for risk factors for atherosclerosis, 
like exercise, blood pressure, cholesterol and body weight. 
 Other combinations of respiratory symptoms than those addressed in this study should 
be examined as risk factors for mortality and lung cancer. 
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 What is the association between respiratory symptoms and risk for cause-specific 
mortality and incidence of lung cancer among persons over 70 years at baseline? 
 Will suppression of respiratory symptoms with anti-inflammatory and bronchodilatory 
drugs in a controlled clinical trial reduce the risks for early death and lung cancer? 
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Appendix 2.     Questionnaire used in the First Asthma Oslo Study 1972,  in English 
 
Lung Department, National Hospital, Oslo 
 
Study of the occurrence of asthma and bronchitis in Oslo 
 
 
Dear inhabitant of Oslo! 
The Lung Department at the National Hospital is performing a study of the occurrence of 
asthma and bronchitis in Oslo. From the population, 20 000 people have been asked to answer 
a questionnaire, and you are one of them. Participation is voluntary, but a high participation 
rate is vital to the study. Because of this, I would kindly ask you to fill out the questionnaire 
and return it in the envelope. If you cannot provide an accurate answer, please answer to the 
best of your ability. If you cannot answer a question, leave it blank. Questions in a thick box 
should be marked in the thick box that is most appropriate. If you should decide not to 
participate, I would appreciate you marking this on the questionnaire and returning it. All 
information will be treated fully confidentially. Thank you in advance! 
Yours sincerely, T. Wessel-Aas, Professor, MD PhD 
1. Is the name and address on the questionnaire correct and complete? Yes/No. If no, 
please provide your full name and address. Name: Address: 
2. When were you born? Day/Month/Year 
3. For how many years have you lived in Oslo? 
4. Please tick that group that best describes your current job status: 
- I am working (housework, education or other work. Please tick this even if you 
presently are on sick leave or are unemployed). 
- I an on disability benefits. Please tell us why: 
- I am not working, for other reasons. Please tell us why: 
(New page) 
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5. Are you or have you been exposed to dust, fumes or noxious vapours (gases) in your 
work? Yes/No 
6. If yes, what kind of dust, fumes or noxious vapours? 
7. Have any of your parents, siblings or children had eczema, hay fever, hives, asthma or 
bronchitis? Yes/No/Don‟t know 
8. Do you usually cough or clear your throat in the morning? Yes/No 
9. Do you usually cough during the rest of the day? Yes/No 
10. When you cough or clear your throat, do you usually bring up phlegm? Yes/No 
11. Do you have a cough for 3 months or more altogether during a year? Yes/No 
12. During the past 2 years, have you had a cough and/or phlegm in connection with a 
cold for more than 3 weeks? Yes, once/Yes, several times/No 
13. Are you more breathless than other people of your own age when walking uphill? 
Yes/No 
14. Are you breathless when you climb two flights of stairs at an ordinary pace? Yes/No 
15. Are you breathless when you walk on level ground at an ordinary pace? Yes/No 
16. Are you breathless when at rest? Yes/No 
17. Do you sometimes have attacks of breathlessness? Yes/No 
18. Have you ever had wheezing in your chest? Yes/No 
19. Have you ever smoked daily for more than 1 year (former smokers please also 
respond)? Yes/No 
20. For how many years altogether have you smoked? __ years. 
21. How many cigarettes did you usually smoke daily? (Factory-rolled and hand-rolled 
together. One pack of tobacco (50 grams) counts as 50 cigarettes) ____ cigarettes. 
22. How many packs of 50 grams did you usually smoke in a pipe weekly? ___ packs. 
23. Did you stop smoking more than 1 year ago? Yes/No 
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24. If yes, how many years ago? ___ years 
Have you ever had any of the diseases listed below? 
25. Eczema. Yes/No/Don‟t know 
26. Hives. Yes/No/Don‟t know 
27. Hay fever. Yes/No/Don‟t know 
Have you ever been treated by a doctor or have you been admitted to hospital for one of 
the diseases listed below? 
28. Asthma. Yes/No/Don‟t know 
29. Bronchitis. Yes/No/Don‟t know 
30. Emphysema (“inflated lungs”). Yes/No/Don‟t know 
31. Pleuritis. Yes/No/Don‟t know 
32. Pulmonary tuberculosis. Yes/No/Don‟t know 
33. Other pulmonary diseases. Yes/No/Don‟t know 
34. Myocardial infarction. Yes/No/Don‟t know 
35. Heart cramp. Yes/No/Don‟t know 
36. Heart failure. Yes/No/Don‟t know 
37. Other heart disease. Yes/No/Don‟t know 
38. Have you ever been treated by a doctor or have you been admitted to hospital for any 
other diseases that can affect respiration? Yes/No/Don‟t know 
39. If yes, please describe which disease:  
 
